Caidya & Simbec-Orion announce strategic combination. Learn More
Fragmented stakeholders? Enrollment volatility? Compressed timelines? Never again.
Caidya’s clinical trial project management brings accountable leadership, integrated governance, and proactive risk management to keep you moving at the speed of science.
Tracy Cyr, MSPH, is a drug development executive with 20+ years of experience across CRO and pharmaceutical organizations. She leads complex global projects through a data-driven approach, strong cross-functional leadership, and a focus on improving outcomes. Her leadership philosophy centers on the project manager as an accountable owner who aligns cross-functional teams to sponsor goals, balances risks and tradeoffs through transparent, data-driven decision-making, and serves as the client advocate across internal teams. Tracy has deep experience supporting lean biotech organizations where speed, clarity, and structured decision-making are critical to successful delivery.
VP & Head, Global Project Management
Complex trials only succeed with full accountability, and our project manager-led model delivers. By maintaining ownership at every step, we ensure global alignment, manage complexity, and:
Our structured cadence, clear ownership, and proactive risk review promote transparency and timely issue resolution.
You set your timeline for a reason. We protect it with critical path management, preemptive activation, enrollment mitigation, and contingency planning.
Disciplined impact assessment and structured amendment execution mean efficiently implemented changes and alignment across teams and vendors.
We’re in this together, so we always clearly communicate data-driven recommendations, like time and cost tradeoffs.
Tracy Cyr - VP & Head, Global Project Management
Our clinical trial project management team delivers your project on time, within budget, and up to exacting quality standards through:
Our priority is doing what’s best for you, your study, and your patients by:
A PM keeps clinical trials on track through disciplined planning, clear milestone governance, and continuous oversight of scope and budget. They maintain transparency around risks and tradeoffs, enabling early course correction before issues impact timelines or costs.
Start-up and enrollment delays are prevented through integrated activation and enrollment planning, structured readiness checks, and proactive recovery plans. This ensures dependencies are identified early and addressed before they affect first patient in (FPI) or recruitment momentum.
Protocol amendments are managed through structured change control, including cross-functional impact assessment and disciplined execution planning. This minimizes downstream disruption across training, systems, vendors, and site operations.
Data quality and safety oversight are maintained through real-time governance, standardized clinical trial data management processes, and consistent operational cadence. This ensures inspection readiness is embedded throughout the study, not addressed only at the end.
Coordination is achieved through a single accountable PM, a defined decision rhythm, and clear escalation pathways. This creates alignment across vendors and functions while reducing complexity for lean sponsor teams.
Global studies are supported through early alignment, country-specific sequencing, and operational plans designed for regional clinical trial regulatory requirements. This enables consistent execution across geographies while respecting local variation.
The PM acts as the client advocate internally and externally, ensuring sponsor priorities are accurately represented in decisions and execution. This includes transparent communication with sites and consistent alignment across internal teams.
Decisions are made quickly through data-driven inputs, empowered PM leadership, and clear accountability structures. This ensures speed without compromising quality, compliance, or operational control.
Your day-to-day point of contact is a single accountable project manager who serves as the central interface across all functions and vendors. Our “one touch point” model ensures clarity, consistency, and efficient communication.
Our PMs bring broad experience across oncology, rare disease, pediatrics, cardiovascular-metabolic, cell & gene therapy, dermatology, and other general medicine therapy areas, enabling them to adapt to both highly complex and high-volume study environments.